Januvia Tablet, Film Coated
Product Images NDC 0006-0277

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Januvia (NDC 0006-0277). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Sitagliptin Chemical Structure (Januvia 01)

Chemical structure of sitagliptin phosphate monohydrate, the active ingredient in JANUVIA. The diagram depicts the molecular arrangement including fluorine-substituted phenyl rings, piperazine, triazole rings, phosphate group, and hydrate component.*

FDA Label Image

Image Of Figure 1 (Januvia 02)

A line graph depicting the least squares mean change from baseline over 24 weeks. The x-axis shows time in weeks, and the y-axis shows the LS mean change from baseline. The graph compares six groups: Placebo, Metformin 500 mg twice daily, Metformin 1000 mg twice daily, Sitagliptin 100 mg once daily, Sitagliptin 50 mg twice daily with Metformin 500 mg twice daily, and Sitagliptin 50 mg twice daily with Metformin 1000 mg twice daily. Data points show different downward trends in LS mean change across the groups over time.*

FDA Label Image

Image Of Figure 2 (Januvia 03)

A line graph comparing the least squares mean change from baseline over 52 weeks between Januvia 100 mg and Glipizide. The x-axis represents weeks from 0 to 52, and the y-axis shows LS mean change from baseline ranging from 0 to -1.5. Both treatments show a decrease below baseline initially, stabilizing and slightly increasing toward week 52.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

Januvia 25 mg tablets label showing sitagliptin as the active ingredient. The label states the strength as 25 mg film-coated oral tablets, with 30 tablets per package. Manufactured by Merck Sharp & Dohme LLC, it includes storage instructions and an image of a round, orange tablet imprinted with '221'.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

Label for Januvia (sitagliptin) tablets, 50 mg strength, oral film-coated tablets. The label indicates a package of 30 tablets with each tablet containing 64.25 mg sitagliptin phosphate equivalent to 50 mg sitagliptin. Manufactured by Merck Sharp & Dohme LLC and labeled for prescription use only.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Label for JANUVIA (sitagliptin) tablets, 100 mg oral film-coated tablets. The label indicates a 30-tablet supply and states the active ingredient equivalence to 100 mg sitagliptin. It is manufactured by Merck Sharp & Dohme LLC and includes storage instructions and the National Drug Code (NDC 0006-0277-31). The label features a visual of a round tablet imprinted with "277."*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.